conjunctivitis arida

(redirected from Dry eye syndrome)
Also found in: Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to Dry eye syndrome: Restasis
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.conjunctivitis arida - abnormal dryness of the conjunctiva and cornea of the eyes; may be due to a systemic deficiency of vitamin A
dryness, waterlessness, xerotes - the condition of not containing or being covered by a liquid (especially water)
References in periodicals archive ?
OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx") has announced that it is set to begin a Phase 2 clinical trial in 72 patients with dry eye syndrome.
The drug candidate is also being studied in patients with dry eye syndrome in the U.
Published human data indicate that RGN-259 can successfully heal ocular surface defects, which most often occur as a result of dry eye syndrome and particularly in patients with moderate-to-severe dry eye.
As part of this IND, the FDA has agreed that Novagali may proceed directly into pivotal Phase III clinical trials in the United States in patients with moderate-to-severe Dry Eye Syndrome.
The trial is a double-masked, placebo-controlled clinical trial to evaluate the safety and efficacy of RGN-259, the Company's proprietary preservative-free eye drops, in patients with dry eye syndrome.
In dry eye syndrome, it is hypothesized that VISMED(R), administered via ocular instillation, will hydrate the surface of the eye preventing dryness and long-term ocular injury.
RGN-259 has been shown to reduce ocular surface defects associated with dry eye syndrome in two animal models when compared to both positive and negative controls.
28, 2015 /PRNewswire-iReach/ --The Global Dry Eye Syndrome Market 2015-2019 report analysts forecast the global dry eye syndrome market to grow at a CAGR of 4.
The acquisition of VISMED(R) brings Lantibio an exciting product to be evaluated for the potential treatment of dry eye syndrome.
Dry eye syndrome is a common ophthalmic disease affecting an estimated 90 million people worldwide.
The authors forecasts the global dry eye syndrome therapeutics market to grow at 6.
Food and Drug Administration to finalize details of the Phase IIb/III trial in patients with dry eye syndrome, which is being sponsored by ReGenTree, LLC.